On July 22, Danaher declined 3.34% in regular trading, trading at approximately $173.14/share with turnover of $3.79 billion, extending the prior session's sharp post-earnings sell-off.

The continued weakness follows the company's Q2 earnings release on July 21, which beat expectations — adjusted EPS of $1.94 vs. $1.83 estimate, revenue of $6.265 billion vs. $6.102 billion estimate — but included Q3 non-GAAP core revenue growth guidance of only 2.0%-3.0%, significantly below Q2's 6.8% pace. Multiple institutions subsequently cut price targets: Morgan Stanley lowered its target to $220 from $255 while maintaining Overweight, and Evercore ISI reduced its target to $205 from $230. The consensus mean target has now fallen to approximately $227.50.

Additionally, the company's recent completion of the approximately $10 billion Masimo acquisition and its Leica Biosystems unit's agreement to acquire StatLab Medical Products have heightened concerns over near-term financial integration pressures, further weighing on investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)